4.8 Article

Targeted-lung delivery of dexamethasone using gated mesoporous silica nanoparticles. A new therapeutic approach for acute lung injury treatment

期刊

JOURNAL OF CONTROLLED RELEASE
卷 337, 期 -, 页码 14-26

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2021.07.010

关键词

Mesoporous silica nanoparticles; Gated nanodevices; TNFR peptide; Dexamethasone delivery; ALI treatment

资金

  1. Spanish government
  2. Spanish Government [RTI2018-100910-B-C41, RTI2018-101599-BC22-AR]
  3. Generalitat Valencia [PROMETEO/2018/024]
  4. Generalitat Valenciana [PROMETEO/2019/065]
  5. Spanish Government (MINECO/AEI/FEDER, UE) [SAF2017-84689-R]

向作者/读者索取更多资源

The new mesoporous silica nanoparticles-based nanodevice can target lung inflammation and reduce cytokine levels, showing promising anti-inflammatory effects in an ALI mouse model, which could be used for improving ALI treatment methods.
Acute lung injury (ALI) is a critical inflammatory syndrome, characterized by increased diffuse inflammation and severe lung damage, which represents a clinical concern due to the high morbidity and mortality in critical patients. In last years, there has been a need to develop more effective treatments for ALI, and targeted drug delivery to inflamed lungs has become an attractive research field. Here, we present a nanodevice based on mesoporous silica nanoparticles loaded with dexamethasone (a glucocorticoid extensively used for ALI treatment) and capped with a peptide that targets the TNFR1 receptor expressed in pro-inflammatory macrophages (TNFR-Dex-MSNs) and avoids cargo leakage. TNFR-Dex-MSNs nanoparticles are preferentially internalized by pro-inflammatory macrophages, which overexpressed the TNFR1 receptor, with the subsequent cargo release upon the enzymatic hydrolysis of the capping peptide in lysosomes. Moreover, TNFR-Dex-MSNs are able to reduce the levels of TNF-alpha and IL-1I3 cytokines in activated pro-inflammatory M1 macrophages. The antiinflammatory effect of TNFR-Dex-MSNs is also tested in an in vivo ALI mice model. The administered nanodevice (intravenously by tail vein injection) accumulated in the injured lungs and the controlled dexamethasone release reduces markedly the inflammatory response (TNF-alpha IL-6 and IL-1I3 levels). The attenuation in lung damage, after treatment with TNFR-Dex-MSNs, is also confirmed by histopathological studies. Besides, the targeted-lung dexamethasone delivery results in a decrease of dexamethasone derived side-effects, suggesting that targeted nanoparticles can be used for therapy in ALI and could help to overcome the clinical limitations of current treatments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据